img

Global CD161 Antibody Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global CD161 Antibody Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal CD161 Antibody Market
Global CD161 Antibody market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, CD161 Antibody industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Globally, CD161 Antibody key companies include BD Biosciences, GeneTex, RayBiotech, LifeSpan BioSciences, BioLegend, Abeomics, Bioss, Novus Biologicals and Tonbo Biosciences, etc. BD Biosciences, GeneTex, RayBiotech are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of CD161 Antibody were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole CD161 Antibody market and estimated to attract more attentions from industry insiders and investors.
CD161 Antibody can be divided into Monoclonal and Polyclonal, etc. Monoclonal is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
CD161 Antibody is widely used in various fields, such as Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP) and Western Blot (WB), etc. Immunochemistry (IHC) provides greatest supports to the CD161 Antibody industry development. In 2022, global % revenue of CD161 Antibody went into Immunochemistry (IHC) filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global CD161 Antibody market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global CD161 Antibody market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


BD Biosciences
GeneTex
RayBiotech
LifeSpan BioSciences
BioLegend
Abeomics
Bioss
Novus Biologicals
Tonbo Biosciences
Bio-Rad
Cell Sciences
Miltenyi Biotec
R&D Systems
BMA Biomedicals
AAT Bioquest
Biobyt
Jingjie PTM BioLab
Segment by Type
Monoclonal
Polyclonal

Segment by Application


Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, CD161 Antibody introduction, etc. CD161 Antibody Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of CD161 Antibody
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CD161 Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Market by Application
1.3.1 Global CD161 Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Immunoprecipitation (IP)
1.3.5 Western Blot (WB)
1.3.6 ELISA
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CD161 Antibody Market Perspective (2018-2033)
2.2 Global CD161 Antibody Growth Trends by Region
2.2.1 CD161 Antibody Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 CD161 Antibody Historic Market Size by Region (2018-2023)
2.2.3 CD161 Antibody Forecasted Market Size by Region (2024-2033)
2.3 CD161 Antibody Market Dynamics
2.3.1 CD161 Antibody Industry Trends
2.3.2 CD161 Antibody Market Drivers
2.3.3 CD161 Antibody Market Challenges
2.3.4 CD161 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue CD161 Antibody by Players
3.1.1 Global CD161 Antibody Revenue by Players (2018-2023)
3.1.2 Global CD161 Antibody Revenue Market Share by Players (2018-2023)
3.2 Global CD161 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of CD161 Antibody, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global CD161 Antibody Market Concentration Ratio
3.4.1 Global CD161 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CD161 Antibody Revenue in 2022
3.5 Global Key Players of CD161 Antibody Head office and Area Served
3.6 Global Key Players of CD161 Antibody, Product and Application
3.7 Global Key Players of CD161 Antibody, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CD161 Antibody Breakdown Data by Type
4.1 Global CD161 Antibody Historic Market Size by Type (2018-2023)
4.2 Global CD161 Antibody Forecasted Market Size by Type (2024-2033)
5 CD161 Antibody Breakdown Data by Application
5.1 Global CD161 Antibody Historic Market Size by Application (2018-2023)
5.2 Global CD161 Antibody Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America CD161 Antibody Market Size (2018-2033)
6.2 North America CD161 Antibody Market Size by Type
6.2.1 North America CD161 Antibody Market Size by Type (2018-2023)
6.2.2 North America CD161 Antibody Market Size by Type (2024-2033)
6.2.3 North America CD161 Antibody Market Share by Type (2018-2033)
6.3 North America CD161 Antibody Market Size by Application
6.3.1 North America CD161 Antibody Market Size by Application (2018-2023)
6.3.2 North America CD161 Antibody Market Size by Application (2024-2033)
6.3.3 North America CD161 Antibody Market Share by Application (2018-2033)
6.4 North America CD161 Antibody Market Size by Country
6.4.1 North America CD161 Antibody Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America CD161 Antibody Market Size by Country (2018-2023)
6.4.3 North America CD161 Antibody Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe CD161 Antibody Market Size (2018-2033)
7.2 Europe CD161 Antibody Market Size by Type
7.2.1 Europe CD161 Antibody Market Size by Type (2018-2023)
7.2.2 Europe CD161 Antibody Market Size by Type (2024-2033)
7.2.3 Europe CD161 Antibody Market Share by Type (2018-2033)
7.3 Europe CD161 Antibody Market Size by Application
7.3.1 Europe CD161 Antibody Market Size by Application (2018-2023)
7.3.2 Europe CD161 Antibody Market Size by Application (2024-2033)
7.3.3 Europe CD161 Antibody Market Share by Application (2018-2033)
7.4 Europe CD161 Antibody Market Size by Country
7.4.1 Europe CD161 Antibody Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe CD161 Antibody Market Size by Country (2018-2023)
7.4.3 Europe CD161 Antibody Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China CD161 Antibody Market Size (2018-2033)
8.2 China CD161 Antibody Market Size by Type
8.2.1 China CD161 Antibody Market Size by Type (2018-2023)
8.2.2 China CD161 Antibody Market Size by Type (2024-2033)
8.2.3 China CD161 Antibody Market Share by Type (2018-2033)
8.3 China CD161 Antibody Market Size by Application
8.3.1 China CD161 Antibody Market Size by Application (2018-2023)
8.3.2 China CD161 Antibody Market Size by Application (2024-2033)
8.3.3 China CD161 Antibody Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia CD161 Antibody Market Size (2018-2033)
9.2 Asia CD161 Antibody Market Size by Type
9.2.1 Asia CD161 Antibody Market Size by Type (2018-2023)
9.2.2 Asia CD161 Antibody Market Size by Type (2024-2033)
9.2.3 Asia CD161 Antibody Market Share by Type (2018-2033)
9.3 Asia CD161 Antibody Market Size by Application
9.3.1 Asia CD161 Antibody Market Size by Application (2018-2023)
9.3.2 Asia CD161 Antibody Market Size by Application (2024-2033)
9.3.3 Asia CD161 Antibody Market Share by Application (2018-2033)
9.4 Asia CD161 Antibody Market Size by Region
9.4.1 Asia CD161 Antibody Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia CD161 Antibody Market Size by Region (2018-2023)
9.4.3 Asia CD161 Antibody Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America CD161 Antibody Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America CD161 Antibody Market Size by Type
10.2.1 Middle East, Africa, and Latin America CD161 Antibody Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America CD161 Antibody Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America CD161 Antibody Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America CD161 Antibody Market Size by Application
10.3.1 Middle East, Africa, and Latin America CD161 Antibody Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America CD161 Antibody Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America CD161 Antibody Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America CD161 Antibody Market Size by Country
10.4.1 Middle East, Africa, and Latin America CD161 Antibody Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America CD161 Antibody Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America CD161 Antibody Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 BD Biosciences
11.1.1 BD Biosciences Company Details
11.1.2 BD Biosciences Business Overview
11.1.3 BD Biosciences CD161 Antibody Introduction
11.1.4 BD Biosciences Revenue in CD161 Antibody Business (2018-2023)
11.1.5 BD Biosciences Recent Developments
11.2 GeneTex
11.2.1 GeneTex Company Details
11.2.2 GeneTex Business Overview
11.2.3 GeneTex CD161 Antibody Introduction
11.2.4 GeneTex Revenue in CD161 Antibody Business (2018-2023)
11.2.5 GeneTex Recent Developments
11.3 RayBiotech
11.3.1 RayBiotech Company Details
11.3.2 RayBiotech Business Overview
11.3.3 RayBiotech CD161 Antibody Introduction
11.3.4 RayBiotech Revenue in CD161 Antibody Business (2018-2023)
11.3.5 RayBiotech Recent Developments
11.4 LifeSpan BioSciences
11.4.1 LifeSpan BioSciences Company Details
11.4.2 LifeSpan BioSciences Business Overview
11.4.3 LifeSpan BioSciences CD161 Antibody Introduction
11.4.4 LifeSpan BioSciences Revenue in CD161 Antibody Business (2018-2023)
11.4.5 LifeSpan BioSciences Recent Developments
11.5 BioLegend
11.5.1 BioLegend Company Details
11.5.2 BioLegend Business Overview
11.5.3 BioLegend CD161 Antibody Introduction
11.5.4 BioLegend Revenue in CD161 Antibody Business (2018-2023)
11.5.5 BioLegend Recent Developments
11.6 Abeomics
11.6.1 Abeomics Company Details
11.6.2 Abeomics Business Overview
11.6.3 Abeomics CD161 Antibody Introduction
11.6.4 Abeomics Revenue in CD161 Antibody Business (2018-2023)
11.6.5 Abeomics Recent Developments
11.7 Bioss
11.7.1 Bioss Company Details
11.7.2 Bioss Business Overview
11.7.3 Bioss CD161 Antibody Introduction
11.7.4 Bioss Revenue in CD161 Antibody Business (2018-2023)
11.7.5 Bioss Recent Developments
11.8 Novus Biologicals
11.8.1 Novus Biologicals Company Details
11.8.2 Novus Biologicals Business Overview
11.8.3 Novus Biologicals CD161 Antibody Introduction
11.8.4 Novus Biologicals Revenue in CD161 Antibody Business (2018-2023)
11.8.5 Novus Biologicals Recent Developments
11.9 Tonbo Biosciences
11.9.1 Tonbo Biosciences Company Details
11.9.2 Tonbo Biosciences Business Overview
11.9.3 Tonbo Biosciences CD161 Antibody Introduction
11.9.4 Tonbo Biosciences Revenue in CD161 Antibody Business (2018-2023)
11.9.5 Tonbo Biosciences Recent Developments
11.10 Bio-Rad
11.10.1 Bio-Rad Company Details
11.10.2 Bio-Rad Business Overview
11.10.3 Bio-Rad CD161 Antibody Introduction
11.10.4 Bio-Rad Revenue in CD161 Antibody Business (2018-2023)
11.10.5 Bio-Rad Recent Developments
11.11 Cell Sciences
11.11.1 Cell Sciences Company Details
11.11.2 Cell Sciences Business Overview
11.11.3 Cell Sciences CD161 Antibody Introduction
11.11.4 Cell Sciences Revenue in CD161 Antibody Business (2018-2023)
11.11.5 Cell Sciences Recent Developments
11.12 Miltenyi Biotec
11.12.1 Miltenyi Biotec Company Details
11.12.2 Miltenyi Biotec Business Overview
11.12.3 Miltenyi Biotec CD161 Antibody Introduction
11.12.4 Miltenyi Biotec Revenue in CD161 Antibody Business (2018-2023)
11.12.5 Miltenyi Biotec Recent Developments
11.13 R&D Systems
11.13.1 R&D Systems Company Details
11.13.2 R&D Systems Business Overview
11.13.3 R&D Systems CD161 Antibody Introduction
11.13.4 R&D Systems Revenue in CD161 Antibody Business (2018-2023)
11.13.5 R&D Systems Recent Developments
11.14 BMA Biomedicals
11.14.1 BMA Biomedicals Company Details
11.14.2 BMA Biomedicals Business Overview
11.14.3 BMA Biomedicals CD161 Antibody Introduction
11.14.4 BMA Biomedicals Revenue in CD161 Antibody Business (2018-2023)
11.14.5 BMA Biomedicals Recent Developments
11.15 AAT Bioquest
11.15.1 AAT Bioquest Company Details
11.15.2 AAT Bioquest Business Overview
11.15.3 AAT Bioquest CD161 Antibody Introduction
11.15.4 AAT Bioquest Revenue in CD161 Antibody Business (2018-2023)
11.15.5 AAT Bioquest Recent Developments
11.16 Biobyt
11.16.1 Biobyt Company Details
11.16.2 Biobyt Business Overview
11.16.3 Biobyt CD161 Antibody Introduction
11.16.4 Biobyt Revenue in CD161 Antibody Business (2018-2023)
11.16.5 Biobyt Recent Developments
11.17 Jingjie PTM BioLab
11.17.1 Jingjie PTM BioLab Company Details
11.17.2 Jingjie PTM BioLab Business Overview
11.17.3 Jingjie PTM BioLab CD161 Antibody Introduction
11.17.4 Jingjie PTM BioLab Revenue in CD161 Antibody Business (2018-2023)
11.17.5 Jingjie PTM BioLab Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global CD161 Antibody Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Monoclonal
Table 3. Key Players of Polyclonal
Table 4. Global CD161 Antibody Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global CD161 Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global CD161 Antibody Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global CD161 Antibody Market Share by Region (2018-2023)
Table 8. Global CD161 Antibody Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global CD161 Antibody Market Share by Region (2024-2033)
Table 10. CD161 Antibody Market Trends
Table 11. CD161 Antibody Market Drivers
Table 12. CD161 Antibody Market Challenges
Table 13. CD161 Antibody Market Restraints
Table 14. Global CD161 Antibody Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global CD161 Antibody Revenue Share by Players (2018-2023)
Table 16. Global Top CD161 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD161 Antibody as of 2022)
Table 17. Global CD161 Antibody Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by CD161 Antibody Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of CD161 Antibody, Headquarters and Area Served
Table 20. Global Key Players of CD161 Antibody, Product and Application
Table 21. Global Key Players of CD161 Antibody, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global CD161 Antibody Revenue Market Share by Type (2018-2023)
Table 25. Global CD161 Antibody Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global CD161 Antibody Revenue Market Share by Type (2024-2033)
Table 27. Global CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global CD161 Antibody Revenue Share by Application (2018-2023)
Table 29. Global CD161 Antibody Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global CD161 Antibody Revenue Share by Application (2024-2033)
Table 31. North America CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America CD161 Antibody Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America CD161 Antibody Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America CD161 Antibody Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe CD161 Antibody Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe CD161 Antibody Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe CD161 Antibody Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 45. China CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 46. China CD161 Antibody Market Size by Type (2024-2033) & (US$ Million)
Table 47. China CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 48. China CD161 Antibody Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia CD161 Antibody Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia CD161 Antibody Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia CD161 Antibody Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia CD161 Antibody Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia CD161 Antibody Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America CD161 Antibody Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America CD161 Antibody Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America CD161 Antibody Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America CD161 Antibody Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America CD161 Antibody Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America CD161 Antibody Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America CD161 Antibody Market Size by Country (2024-2033) & (US$ Million)
Table 63. BD Biosciences Company Details
Table 64. BD Biosciences Business Overview
Table 65. BD Biosciences CD161 Antibody Product
Table 66. BD Biosciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 67. BD Biosciences Recent Developments
Table 68. GeneTex Company Details
Table 69. GeneTex Business Overview
Table 70. GeneTex CD161 Antibody Product
Table 71. GeneTex Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 72. GeneTex Recent Developments
Table 73. RayBiotech Company Details
Table 74. RayBiotech Business Overview
Table 75. RayBiotech CD161 Antibody Product
Table 76. RayBiotech Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 77. RayBiotech Recent Developments
Table 78. LifeSpan BioSciences Company Details
Table 79. LifeSpan BioSciences Business Overview
Table 80. LifeSpan BioSciences CD161 Antibody Product
Table 81. LifeSpan BioSciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 82. LifeSpan BioSciences Recent Developments
Table 83. BioLegend Company Details
Table 84. BioLegend Business Overview
Table 85. BioLegend CD161 Antibody Product
Table 86. BioLegend Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 87. BioLegend Recent Developments
Table 88. Abeomics Company Details
Table 89. Abeomics Business Overview
Table 90. Abeomics CD161 Antibody Product
Table 91. Abeomics Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 92. Abeomics Recent Developments
Table 93. Bioss Company Details
Table 94. Bioss Business Overview
Table 95. Bioss CD161 Antibody Product
Table 96. Bioss Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 97. Bioss Recent Developments
Table 98. Novus Biologicals Company Details
Table 99. Novus Biologicals Business Overview
Table 100. Novus Biologicals CD161 Antibody Product
Table 101. Novus Biologicals Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 102. Novus Biologicals Recent Developments
Table 103. Tonbo Biosciences Company Details
Table 104. Tonbo Biosciences Business Overview
Table 105. Tonbo Biosciences CD161 Antibody Product
Table 106. Tonbo Biosciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 107. Tonbo Biosciences Recent Developments
Table 108. Bio-Rad Company Details
Table 109. Bio-Rad Business Overview
Table 110. Bio-Rad CD161 Antibody Product
Table 111. Bio-Rad Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 112. Bio-Rad Recent Developments
Table 113. Cell Sciences Company Details
Table 114. Cell Sciences Business Overview
Table 115. Cell Sciences CD161 Antibody Product
Table 116. Cell Sciences Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 117. Cell Sciences Recent Developments
Table 118. Miltenyi Biotec Company Details
Table 119. Miltenyi Biotec Business Overview
Table 120. Miltenyi Biotec CD161 Antibody Product
Table 121. Miltenyi Biotec Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 122. Miltenyi Biotec Recent Developments
Table 123. R&D Systems Company Details
Table 124. R&D Systems Business Overview
Table 125. R&D Systems CD161 Antibody Product
Table 126. R&D Systems Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 127. R&D Systems Recent Developments
Table 128. BMA Biomedicals Company Details
Table 129. BMA Biomedicals Business Overview
Table 130. BMA Biomedicals CD161 Antibody Product
Table 131. BMA Biomedicals Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 132. BMA Biomedicals Recent Developments
Table 133. AAT Bioquest Company Details
Table 134. AAT Bioquest Business Overview
Table 135. AAT Bioquest CD161 Antibody Product
Table 136. AAT Bioquest Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 137. AAT Bioquest Recent Developments
Table 138. Biobyt Company Details
Table 139. Biobyt Business Overview
Table 140. Biobyt CD161 Antibody Product
Table 141. Biobyt Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 142. Biobyt Recent Developments
Table 143. Jingjie PTM BioLab Company Details
Table 144. Jingjie PTM BioLab Business Overview
Table 145. Jingjie PTM BioLab CD161 Antibody Product
Table 146. Jingjie PTM BioLab Revenue in CD161 Antibody Business (2018-2023) & (US$ Million)
Table 147. Jingjie PTM BioLab Recent Developments
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CD161 Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global CD161 Antibody Market Share by Type: 2022 VS 2033
Figure 3. Monoclonal Features
Figure 4. Polyclonal Features
Figure 5. Global CD161 Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global CD161 Antibody Market Share by Application: 2022 VS 2033
Figure 7. Immunochemistry (IHC) Case Studies
Figure 8. Immunofluorescence (IF) Case Studies
Figure 9. Immunoprecipitation (IP) Case Studies
Figure 10. Western Blot (WB) Case Studies
Figure 11. ELISA Case Studies
Figure 12. Others Case Studies
Figure 13. CD161 Antibody Report Years Considered
Figure 14. Global CD161 Antibody Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global CD161 Antibody Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global CD161 Antibody Market Share by Region: 2022 VS 2033
Figure 17. Global CD161 Antibody Market Share by Players in 2022
Figure 18. Global Top CD161 Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD161 Antibody as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by CD161 Antibody Revenue in 2022
Figure 20. North America CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America CD161 Antibody Market Share by Type (2018-2033)
Figure 22. North America CD161 Antibody Market Share by Application (2018-2033)
Figure 23. North America CD161 Antibody Market Share by Country (2018-2033)
Figure 24. United States CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Canada CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. Europe CD161 Antibody Market Size YoY (2018-2033) & (US$ Million)
Figure 27. Europe CD161 Antibody Market Share by Type (2018-2033)
Figure 28. Europe CD161 Antibody Market Share by Application (2018-2033)
Figure 29. Europe CD161 Antibody Market Share by Country (2018-2033)
Figure 30. Germany CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. France CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. U.K. CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Italy CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Russia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Nordic Countries CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. China CD161 Antibody Market Size YoY (2018-2033) & (US$ Million)
Figure 37. China CD161 Antibody Market Share by Type (2018-2033)
Figure 38. China CD161 Antibody Market Share by Application (2018-2033)
Figure 39. Asia CD161 Antibody Market Size YoY (2018-2033) & (US$ Million)
Figure 40. Asia CD161 Antibody Market Share by Type (2018-2033)
Figure 41. Asia CD161 Antibody Market Share by Application (2018-2033)
Figure 42. Asia CD161 Antibody Market Share by Region (2018-2033)
Figure 43. Japan CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. South Korea CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. China Taiwan CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Southeast Asia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. India CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Australia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America CD161 Antibody Market Size YoY (2018-2033) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America CD161 Antibody Market Share by Type (2018-2033)
Figure 51. Middle East, Africa, and Latin America CD161 Antibody Market Share by Application (2018-2033)
Figure 52. Middle East, Africa, and Latin America CD161 Antibody Market Share by Country (2018-2033)
Figure 53. Brazil CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Mexico CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Turkey CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. Saudi Arabia CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Israel CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 58. GCC Countries CD161 Antibody Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 59. BD Biosciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 60. GeneTex Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 61. RayBiotech Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 62. LifeSpan BioSciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 63. BioLegend Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 64. Abeomics Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 65. Bioss Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 66. Novus Biologicals Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 67. Tonbo Biosciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 68. Bio-Rad Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 69. Cell Sciences Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 70. Miltenyi Biotec Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 71. R&D Systems Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 72. BMA Biomedicals Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 73. AAT Bioquest Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 74. Biobyt Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 75. Jingjie PTM BioLab Revenue Growth Rate in CD161 Antibody Business (2018-2023)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries